QUOTE AND NEWS
newratings.com  May 28  Comment 
WASHINGTON (dpa-AFX) - Valeant Pharmaceuticals International Inc.'s (VRX, VRX.TO) wholly owned subsidiary, Salix Pharmaceuticals Inc., has received FDA approval for Xifaxan 550 mg for the treatment of irritable bowel syndrome with diarrhea in...
newratings.com  May 5  Comment 
WASHINGTON (dpa-AFX) - Valeant Pharmaceuticals International Inc.'s (VRX, VRX.TO) wholly owned subsidiary, Salix Pharmaceuticals Inc., has received FDA approval for Xifaxan 550 mg for the treatment of irritable bowel syndrome with diarrhea in...
FiercePharma  Apr 29  Comment 
Following the fold-in of its recent $11.1 billion pickup of Salix Pharmaceuticals, on Wednesday, Valeant raised both its profit and revenue forecasts for the year. But things are already looking good for the Canadian drugmaker, which topped...
FiercePharma  Apr 6  Comment 
After closing its deal for Salix Pharmaceuticals, Valeant wasted no time getting down to business with the cost-cutting it's known for. And now, North Carolina's Triangle area has another 250-plus pharma layoffs to add to a growing list.
Reuters  Apr 1  Comment 
Canada's Valeant Pharmaceuticals International Inc completed its $10.96 billion purchase of Salix Pharmaceuticals Ltd, the acquisitive company said on Wednesday.
FierceBiotech  Mar 26  Comment 
Gastro drug developer Synergy Pharmaceuticals is considering putting itself up for sale, Bloomberg reports, perhaps emboldened by the high price secured by competitor Salix Pharmaceuticals.
FiercePharma  Mar 19  Comment 
Valeant wasn't the only one that scored a win when Salix Pharmaceuticals agreed to its $173-per-share buyout offer. Two former Salix execs--who left the company recently amid inventory issues--will make a pretty penny on the deal as well.
Benzinga  Mar 18  Comment 
Analysts at Jefferies downgraded Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) from Buy to Hold. The price target for Salix Pharmaceuticals has been raised from $149.00 to $173.00. Salix Pharmaceuticals shares have gained 51.17% over the past 52...
Benzinga  Mar 18  Comment 
FiercePharma  Mar 17  Comment 
As Endo showed last week with its failed $10 billion bid for North Carolina's Salix, it's willing to shell out some serious dough if the right target comes along. The question is, what's left?




RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing, and commercializing prescription drugs used in the treatment of a variety of gastrointestinal diseases. The company has a number of products currently approved for sales. These include Colazal (balsalazide disodium) for the treatment of mild to moderate active ulcerative colitis, Azasan (azathioprine) immuno-suppressive therapy for renal homo-transplant rejection and rheumatoid arthritis, and Anusol/Proctocort (hydrocortisone) for the relief of inflammatory dermatoses and hemorrhoids. In May 2004, the company received final Food and Drug Administration (FDA) approval for Xifaxan (rifaximin), an oral antibiotic for the treatment of traveler's diarrhea. Salix Pharmaceuticals is working on additional indications for Xifaxan, as well as a granulated formulation of mesalamine a common treatment option for ulcerative colitis.

Salix subsequently added new products to its portfolio including Visicol, indicated for colon cleansing prior to colonoscopy OsmoPrep, a next-generation Visicol which was launched in June 2006 and MoviPrep, a liquid bowel cleansing agent which was launched in October 2006. While Visicol and OsmoPrep were acquired by the company through its merger with InKine Pharmaceutical, exclusive U.S. in-licensing rights for MoviPrep were acquired from Norgine B.V. Recent additions to the product portfolio include Sanvar IR, indicated for the treatment of acute esophageal variceal bleeding (EVB) two hospital-based products, Pepcid Oral Suspension (indicated for several gastrointestinal indications including the treatment of duodenal ulcer, benign gastric ulcer and gastroesophageal reflux disease) and Diuril Oral Suspension (an adjunctive therapy in edema associated with several conditions including hepatic cirrhosis), from Merck and metoclopramide Zydis, indicated for short term (4 12 weeks) therapy for adults with symptomatic documented gastroesophageal reflux who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastric stasis.

Salix focuses primarily on the U.S. pharmaceutical market, promoting its drugs through its specialized sales force. Management also seeks to form strategic alliances to market its products outside the U.S. in order to avoid the significant costs, risks, and infrastructure inherent in assembling an international sales force. Salix is located in Morrisville, NC and employs roughly 240 professionals.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki